Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to raise funds due to its urgent financial situation and lack of product revenue [1][2]. Company Overview - Puxi Pharmaceutical focuses on the field of immune inflammation, positioning itself as a leader in localized delivery targeted therapies [1]. - The company was established in 2016 and has developed a core technology platform centered on innovative design and localized delivery [1]. - As of September 2025, the company reported cash and cash equivalents of only 155 million RMB, highlighting its urgent need for financing through the IPO [1]. Product Pipeline - The core product, PG-011 (Pumexitinib), is a JAK1/JAK2 inhibitor designed for external use, with formulations in gel and nasal spray currently in late-stage clinical trials [2][3]. - Pumexitinib gel is the first JAK inhibitor gel globally for treating atopic dermatitis, having completed Phase III trials for adults and adolescents aged 12 to 17 [2]. - The nasal spray formulation is the first clinical-stage JAK inhibitor for treating seasonal allergic rhinitis, currently in Phase III trials for adults [3]. Market Potential - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion by 2024, with a compound annual growth rate (CAGR) of 4.1% [4]. - The Chinese autoimmune disease drug market is expected to expand from 16.2 billion RMB in 2019 to 32.8 billion RMB by 2024, with a much higher CAGR of 15.1% [6]. Competitive Landscape - The JAK inhibitor market is highly competitive, with multiple oral JAK1 inhibitors already approved in China for treating moderate to severe atopic dermatitis [8]. - Puxi Pharmaceutical faces significant challenges as a latecomer in a crowded market, needing to establish differentiation in efficacy, safety, or compliance [8]. Commercialization Strategy - The company has signed an exclusive commercialization agreement with Jichuan Pharmaceutical for Pumexitinib nasal spray in China, receiving up to 100 million RMB in payment [12]. - The success of Puxi Pharmaceutical's products will heavily depend on the approval timelines and outcomes of negotiations with health insurance for pricing [10][12].

Core Viewpoint - The article discusses the strategic collaboration between Puxi Pharmaceutical and Jichuan Pharmaceutical Group for the development and commercialization of Pumeixin nasal spray, a novel JAK inhibitor aimed at treating allergic rhinitis, which is expected to be the world's first nasal spray JAK inhibitor [2][3]. Group 1: Collaboration Details - Puxi Pharmaceutical has entered into a strategic cooperation agreement with Jichuan Pharmaceutical, with a maximum transaction value of 100 million RMB, including an upfront payment of 40 million RMB and milestone payments up to 60 million RMB [2]. - Jichuan Pharmaceutical will obtain exclusive commercialization rights for the product in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [2]. Group 2: Product Development and Market Potential - Pumeixin is a self-developed JAK1/2 inhibitor with complete intellectual property rights, specifically designed for allergic rhinitis treatment, and is anticipated to provide a groundbreaking treatment option for patients [3]. - The product has completed multiple Phase I/II clinical studies and is currently undergoing Phase III clinical research after receiving approval from the Chinese National Medical Products Administration (NMPA) [3]. Group 3: Company Focus and Pipeline - Puxi Pharmaceutical specializes in innovative drugs for immune/inflammatory diseases, with a product pipeline that includes treatments for dermatology, respiratory, and ophthalmology conditions [3]. - Core products include Pumeixin gel for atopic dermatitis, Pumeixin nasal spray for allergic rhinitis, PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma, all of which have global leading potential as innovative drugs [3].

Company Announcements - Litong Electronics clarifies that its liquid cooling product development is still in the early discussion stage, and it does not have specific plans for product development or production [2] - Changfei Fiber announces that the global fiber optic cable market environment is normal, and new products related to data centers account for a small proportion of total demand [2] - Rundu Co., Ltd. has a Class 1 innovative drug, but the approval for its injection product remains uncertain [3] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment [3] Investment & Contracts - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization cooperation agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. [4] Equity Changes - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan to Fujian Mingao for a total price of 120 million yuan, which will help resolve historical debt issues [5] Share Buybacks - Lexin Technology plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [6] - XGIMI Technology also plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [7] Business Performance - Chip导科技 reports a revenue of 394 million yuan for 2025, with a net profit of 106 million yuan, reflecting a 4.91% decrease year-on-year [8] - Sainz plans to engage in molybdenum processing and sales, aiming to recover rhenium [9] - Shenghe Resources announces the unilateral termination of its strategic cooperation with ETM, and it will take legal measures to protect its rights [10] - Lianyun Technology reports a net profit growth of 20.36% for 2025, driven by increased demand for storage products [10] - Shanghai Yizhong reports a staggering net profit growth of 819.42% for 2025, attributed to the inclusion of its core product in the national medical insurance directory [11] Other News - Beiyinmei's controlling shareholder's restructuring plan has been approved by the creditors' meeting, which may lead to changes in shareholder equity [12] - Changchun High-tech's subsidiary has received acceptance for a clinical trial application for a new drug [13][14] - Dingxin Communications' vice president has been warned and fined for suspected short-term trading of company stock [15]

Core Viewpoint - Puxi Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and Minyin Capital acting as joint sponsors [1] Group 1: Company Overview - Puxi Pharmaceutical is a biotechnology company focused on the field of immune inflammation [1] - The company’s product, Pumexitin gel, is a JAK inhibitor gel for the treatment of atopic dermatitis, which has completed Phase III clinical trials for adults and adolescents aged 12 to 17, and is expanding to children aged 2 to 11 [1] - Pumexitin nasal spray is the world's first clinical-stage JAK inhibitor nasal spray for the treatment of seasonal allergic rhinitis, currently in Phase III clinical trials for adults and expanding to adolescents with seasonal allergic rhinitis and adults with perennial allergic rhinitis [1]

Company Overview - Beijing Puxi Pharmaceutical Technology Co., Ltd. (Puxi Pharma) focuses on the field of immune inflammation and aims to be a leader in localized targeted therapies. The company was established in 2016 and emphasizes innovative design and precise localized delivery in treating chronic inflammatory diseases [3][4] - Puxi Pharma has developed a core product, PG-011 (Pumexitin), which includes two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis. The company is also exploring additional indications for Pumexitin [4] Product Pipeline - PG-011 (Pumexitin) Gel: The world's first JAK inhibitor gel for treating atopic dermatitis, with completed Phase III clinical trials for adults and adolescents aged 12 to 17. The company is expanding its indications to include children aged 2 to 11 [4] - PG-011 (Pumexitin) Nasal Spray: The first clinical-stage JAK inhibitor nasal spray for seasonal allergic rhinitis (SAR), currently in Phase III trials for adults. The company is also expanding its indications to include adolescents and adults with perennial allergic rhinitis (PAR) [4] - PG-033 Tablet: A TRPV3 inhibitor in Phase I trials, targeting pruritus associated with neurodermatitis and other conditions with unmet medical needs [5] - PG-018 Tablet: A dual-target JAK1-ROCK inhibitor for autoimmune kidney diseases, currently in Phase I trials, aiming to provide synergistic clinical benefits [5] - PG-040 Eye Drops: A dual-target ROCK-JAK eye drop for glaucoma, expected to offer better neuroprotection compared to traditional therapies [6] Financial Information - For the fiscal year 2024, Puxi Pharma reported net income of RMB 11.22 million, with losses of approximately RMB 178.5 million. The losses for the nine months ending September 30, 2024, and 2025 were RMB 132.6 million and RMB 124.98 million, respectively [7][8][9] Industry Overview - The global autoimmune disease drug market is projected to grow from USD 116.9 billion in 2019 to USD 143.1 billion in 2024, with a CAGR of 4.1%. It is expected to reach USD 179.5 billion by 2028 and USD 217 billion by 2033 [10] - The Chinese autoimmune disease drug market is expected to grow from RMB 16.2 billion in 2019 to RMB 32.8 billion in 2024, with a CAGR of 15.1%. Projections indicate it will reach RMB 87 billion by 2028 and RMB 219.6 billion by 2033 [13] - The global allergy disease drug market is anticipated to increase from USD 45.5 billion in 2019 to USD 68.8 billion in 2024, with a CAGR of 8.6%. It is expected to reach USD 98.5 billion by 2028 and USD 131.1 billion by 2033 [15] - The Chinese allergy disease drug market is projected to grow from RMB 30.5 billion in 2019 to RMB 57.5 billion in 2024, with a CAGR of 13.5%. It is expected to reach RMB 108.9 billion by 2028 and RMB 293.8 billion by 2033 [17]

Core Viewpoint - Puxi Pharmaceuticals has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and Minyin Capital serving as joint sponsors [1] Company Overview - Puxi Pharmaceuticals focuses on the immuno-inflammatory field and has developed the world's first JAK inhibitor gel, Pumexitin Gel, for the treatment of atopic dermatitis, which has completed Phase III clinical trials for adults and adolescents aged 12 to 17, and is expanding to children aged 2 to 11 [1] - The company is also developing Pumexitin Nasal Spray, the world's first clinical-stage JAK inhibitor nasal spray for seasonal allergic rhinitis, currently in Phase III clinical trials for adults and expanding to adolescents and adults with perennial allergic rhinitis [1] - PG-033 tablets, a TRPV3 inhibitor with first-in-class potential for pruritus, are in Phase I clinical research, targeting stubborn pruritus related to Omstead syndrome and hyperkeratosis [1] - PG-018 tablets, a JAK1-ROCK dual-target inhibitor for autoimmune kidney disease, are also in Phase I clinical research [1] - PG-040 eye drops, a ROCK-JAK dual-target eye drop, are being developed as a new treatment option for glaucoma [1] Market Potential - The market for drugs treating autoimmune and allergic diseases is experiencing rapid growth both globally and in China [1] - The market for atopic dermatitis drugs in China is projected to grow from 11 billion RMB in 2024 to 50.2 billion RMB by 2033 [1]

Company Overview - Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharmaceutical) focuses on immunoinflammatory diseases and aims to be a leader in localized targeted therapies [4] - The company was established in 2016 and emphasizes innovative design and precise localized delivery in treating chronic inflammatory diseases [4] - Puqi Pharmaceutical has developed a pipeline of innovative products based on its understanding of immune signaling pathways, particularly the JAK-STAT pathway [4] Product Pipeline - Core product PG-011 (Pumeixinine) includes two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trials [5] - PG-033 is a tablet for pruritus, currently in Phase I trials, targeting conditions with unmet medical needs [6] - PG-018 is a dual-target JAK1-ROCK inhibitor for autoimmune kidney diseases, also in Phase I trials [6] - PG-040 is a dual-target eye drop for glaucoma, aiming to provide better neuroprotection compared to traditional therapies [7] Financial Performance - For the fiscal year 2024, the company reported net income of 11.22 million RMB, with losses of approximately 178.5 million RMB [8] - The financial data for the nine months ending September 30, 2024, shows net income of 819,000 RMB and losses of 132.6 million RMB [8] Industry Overview - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion in 2024, with a CAGR of 4.1% [9] - The Chinese autoimmune disease drug market is expected to increase from 16.2 billion RMB in 2019 to 32.8 billion RMB in 2024, with a CAGR of 15.1% [12] - The global allergy disease drug market is anticipated to rise from $45.5 billion in 2019 to $68.8 billion in 2024, with a CAGR of 8.6% [14] - The Chinese allergy disease drug market is projected to grow from 30.5 billion RMB in 2019 to 57.5 billion RMB in 2024, with a CAGR of 13.5% [16] Market Potential for Atopic Dermatitis - The number of atopic dermatitis patients in China is expected to reach 72.9 million by 2024, with a CAGR of 2.1% from 2019 to 2024 [18] - The market for atopic dermatitis drugs in China is projected to grow to 11 billion RMB in 2024, with a CAGR of 28.1% from 2024 to 2028 [20]